SequelSEC

Palomino Laboratories Inc. PALX

Semiconductors & Related Devices · CIK 0001938569 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$2.70M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Palomino Laboratories Inc. (PALX) reported net income of -$3.16M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Palomino Laboratories Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Semiconductors & Related Devices.

Income

Palomino Laboratories Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$2.70M-$6.12K-$83.94K
Net income-$3.16M-$16.20K-$83.94K
Research & developmentUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 6.71Mshares 1.52Mshares 5.00M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.47$-0.01$-0.02
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$2.70M$6.12K$83.94K
Selling & marketingUnavailableUnavailableUnavailable

Balance

Palomino Laboratories Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$8.12M$134.66K$380
Total assets$8.43M$138.12K$380
Current assets$8.43M$138.12K$380
Total liabilities$336.46K$156.43K$111.62K
Current liabilities$336.46K$6.43K$111.62K
Total equity incl. NCI$8.10M-$18.31K-$18.31K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$55.69K$3.29KUnavailable

Cash flow

Palomino Laboratories Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$1.28M-$4.87K-$79.38K
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailable
Financing cash flow$9.27M$195.44K$79.26K
Net change in cash$7.99M-$4.87KUnavailable
Stock-based compensation$1.44MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Palomino Laboratories Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio25.07x21.48x0.00x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PALX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAOI ADI AIP ALAB ALGM ALMU AMAT AMBA AMBQ AMD AMKR AOSL

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.